Study of High-sensitivity C-reactive Protein to Albumin Ratio in Metabolic Fatty Liver Disease and Liver Fibrosis

What this Trial Is About

Researchers are investigating the relationship between a new inflammatory marker called high-sensitivity C-reactive protein to albumin ratio hsCAR and metabolic dysfunction-associated fatty liver disease MAFLD. This observational study aims to find out if hsCAR can help identify patients with MAFLD and whether it can detect liver fibrosis complications in these patients. The study uses data from participants in the NHANES database to explore these questions. The study evaluates participants by measuring liver steatosis and fibrosis using ultrasound-based indices. Participants are grouped based on their controlled attenuation parameter and liver stiffness measurements to compare non-MAFLD and MAFLD groups, as well as non-fibrosis and fibrosis groups. The hsCAR marker is used as an inflammatory indicator to assess disease severity across these groups. Participants undergo evaluations at baseline including controlled attenuation parameter and liver stiffness measurement to assess liver health. The study uses multivariate analyses and subgroup assessments to explore the link between hsCAR and MAFLD. The total participation involves a cross-sectional assessment using existing clinical and ultrasound data, focusing on these measurements and inflammatory markers to understand liver disease severity and fibrosis presence.

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study